Breast Imaging

How Should You Image a Suspicious Breast Mass Found on Ultrasound in a Pregnant Patient?

·
How Should You Image a Suspicious Breast Mass Found on Ultrasound in a Pregnant Patient?

A 32-year-old patient, 24 weeks pregnant with her second child, presents to your clinic for follow-up. She felt a new, firm lump in her left breast two weeks ago. You ordered an initial ultrasound, and the report is now on your screen: a 1.5 cm irregular, hypoechoic mass with indistinct margins, categorized as BI-RADS 4C (moderately suspicious). The immediate clinical question is no longer if you should act, but how. What is the appropriate next imaging step to evaluate this highly concerning finding in a pregnant patient, balancing diagnostic yield with maternal and fetal safety? This article provides a narrative workflow for this specific scenario, where the American College of Radiology (ACR) Appropriateness Criteria rate an ultrasound of the axilla as Usually Appropriate to guide the next critical steps in management.

Who Fits This Clinical Scenario?

This guidance is specifically for a pregnant female of any age who has a palpable breast mass where an initial breast ultrasound has already been performed and the findings are suspicious or highly suggestive of malignancy (e.g., BI-RADS 4 or 5). The key distinction is that this workflow begins after the initial diagnostic imaging has raised a significant concern for cancer.

This article does not apply to several similar, but distinct, clinical situations:

  • Initial Imaging: If your pregnant patient has a palpable mass but has not yet had any imaging, the workup is different. The initial study choice depends on age. This workflow is for the next step after a suspicious initial ultrasound.
  • Benign or Probably Benign US Findings: If the initial ultrasound shows a simple cyst, a classic fibroadenoma, or another finding categorized as BI-RADS 2 (Benign) or 3 (Probably Benign), the management pathway involves follow-up or reassurance, not the aggressive workup detailed here.
  • Screening: This guidance is for a diagnostic workup of a palpable finding, not for asymptomatic breast cancer screening in a pregnant patient, which has its own set of recommendations based on age and risk factors.

Correctly identifying your patient’s place in the diagnostic sequence is crucial for ordering the right test at the right time.

What Diagnoses Are You Working Up in This Scenario?

When a suspicious solid mass is identified in a pregnant patient, the differential diagnosis is focused and driven by the need to exclude malignancy.

The primary concern is Pregnancy-Associated Breast Cancer (PABC). Defined as breast cancer diagnosed during pregnancy, lactation, or within one year of delivery, PABC presents a unique challenge. These cancers are often diagnosed at a more advanced stage, partly because physiologic breast changes like increased density and nodularity can mask a palpable mass and delay presentation. The hormonal environment of pregnancy may also contribute to more aggressive tumor biology in some cases. The entire imaging and biopsy workflow is designed to rapidly confirm or exclude this diagnosis.

While less likely to appear suspicious on ultrasound, other entities must be considered. A lactating adenoma is a benign tumor that can grow rapidly during pregnancy and sometimes exhibit features that mimic malignancy, such as irregular margins or posterior acoustic shadowing. Similarly, a complex galactocele (a milk-filled cyst) can have internal debris and thick walls, appearing as a complex cystic and solid mass that warrants further investigation. A pre-existing fibroadenoma can also undergo lactational changes, increasing in size and vascularity, which can occasionally raise suspicion on an initial sonogram. However, given suspicious sonographic features, the possibility of PABC must take precedence and drive the workup.

Why Is Axillary Ultrasound the Recommended Next Step?

After identifying a suspicious primary breast lesion on ultrasound, the immediate next step in staging is to evaluate the axillary lymph nodes. For this reason, US axilla is rated Usually Appropriate by the ACR. This non-invasive study uses no ionizing radiation (0 mSv) and is entirely safe for both the mother and fetus. Its purpose is to identify any lymph nodes that appear morphologically suspicious for metastatic involvement, typically characterized by cortical thickening, rounded shape, and effacement or loss of the normal fatty hilum. Finding suspicious axillary nodes significantly alters the patient’s clinical stage and subsequent surgical and systemic therapy planning.

Several other procedures are also rated Usually Appropriate and are often performed concurrently or sequentially:

  • US breast (repeat/targeted): A second, comprehensive ultrasound of the breast is often performed at the time of the axillary evaluation to fully characterize the primary lesion, identify any additional lesions, and precisely map the location for a subsequent biopsy.
  • Image-guided core biopsy breast: This is the essential diagnostic step to obtain tissue for pathologic analysis. It is not merely an imaging study but a procedure guided by imaging (usually ultrasound). A core needle biopsy is strongly preferred over fine-needle aspiration (FNA) because it provides tissue architecture, allowing pathologists to determine if a cancer is invasive and to assess hormone receptor status.
  • Mammography diagnostic (or Digital breast tomosynthesis): Though it involves a low dose of ionizing radiation (0.1-1 mSv), diagnostic mammography with abdominal shielding is considered safe in pregnancy, with negligible fetal radiation exposure. It is crucial for detecting suspicious microcalcifications or assessing the extent of disease, features that may be missed by ultrasound, especially in a dense breast.

Conversely, some advanced imaging modalities are rated lower for this specific scenario:

  • MRI breast without and with IV contrast is rated Usually not appropriate. The primary concern is the use of gadolinium-based contrast agents (GBCAs). GBCAs are known to cross the placenta and enter the fetal circulation, with unknown long-term consequences. Therefore, contrast-enhanced MRI is avoided during pregnancy unless the potential benefit unequivocally outweighs the theoretical fetal risk, a decision made in a multidisciplinary setting.
  • Sestamibi MBI (Molecular Breast Imaging) is also Usually not appropriate due to the systemic administration of a radiotracer, which results in a higher radiation dose (1-10 mSv) and is contraindicated during pregnancy.

What’s Next After Axillary Ultrasound? Downstream Workflow

The results of the axillary ultrasound and subsequent biopsies create a clear decision tree for patient management.

If the axillary US is positive (suspicious nodes found):
The next step is to obtain a tissue sample from the abnormal lymph node(s), typically via US-guided FNA or core biopsy. This is often performed at the same time as the biopsy of the primary breast mass. If both biopsies confirm malignancy, the patient has, at minimum, stage II breast cancer. This finding immediately triggers a consultation with a multidisciplinary team—including a breast surgeon, medical oncologist, radiation oncologist, and maternal-fetal medicine specialist—to formulate a treatment plan that is safe for the gestational age.

If the axillary US is negative (no suspicious nodes):
The focus remains on diagnosing the primary breast mass. An image-guided core biopsy of the breast lesion is performed. If the biopsy confirms malignancy, the patient is still referred for multidisciplinary consultation. While the negative axillary US is reassuring, a surgical staging procedure, such as a sentinel lymph node biopsy, will likely still be part of the surgical plan to microscopically evaluate the nodes.

If the breast biopsy is benign:
If the core biopsy reveals a benign entity like a lactating adenoma or fibroadenoma, and the imaging findings are concordant with the pathology, the patient can be reassured. A management plan for clinical observation or short-term imaging follow-up after delivery may be recommended to ensure stability.

Pitfalls to Avoid (and When to Get Help)

Navigating a potential cancer diagnosis during pregnancy requires vigilance to avoid common pitfalls.

  • Attribution Error: Do not automatically attribute a new, persistent palpable breast mass to normal physiologic changes of pregnancy. Any dominant or suspicious lump warrants an imaging workup, starting with ultrasound.
  • Incomplete Staging: Failing to perform a dedicated, thorough ultrasound of the axilla at the time of the diagnostic breast workup is a significant omission. Axillary status is one of the most important prognostic factors.
  • Radiation Phobia: Unnecessarily avoiding a diagnostic mammogram due to fears of radiation can lead to an incomplete diagnosis. When indicated, mammography with abdominal shielding provides critical information with minimal risk to the fetus.
  • Premature MRI Orders: Ordering a contrast-enhanced breast MRI without a compelling, multidisciplinary-backed reason is inappropriate due to the unknown risks of gadolinium exposure to the fetus.

If you encounter a BI-RADS 4 or 5 lesion in a pregnant patient, immediate escalation to a breast imaging specialist and a breast surgeon is the appropriate next step.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to breast imaging in pregnant and lactating patients, refer to our parent guide. Additional tools can help you apply these criteria in your practice.

Frequently Asked Questions

Why is MRI with contrast ‘Usually Not Appropriate’ if it’s the most sensitive test for breast cancer staging?

While breast MRI is highly sensitive, its use during pregnancy is limited by the need for a gadolinium-based contrast agent. These agents cross the placenta and are excreted by the fetal kidneys into the amniotic fluid, where they can be re-ingested by the fetus. The long-term effects of this exposure are unknown, so the procedure is avoided unless the potential diagnostic benefit is deemed to outweigh the theoretical risks by a multidisciplinary team.

Is diagnostic mammography truly safe during pregnancy?

Yes. When performed with proper lead shielding over the abdomen and pelvis, the radiation dose to the fetus from a diagnostic mammogram or tomosynthesis is negligible—far below the threshold known to cause harm. The diagnostic benefit of evaluating for microcalcifications or assessing the extent of disease often outweighs this minimal risk.

If the axillary ultrasound is negative, does the patient still need a lymph node biopsy?

Yes, if the primary breast mass is proven to be cancer. Ultrasound can only detect macroscopic disease in lymph nodes. A surgical procedure, typically a sentinel lymph node biopsy, is still necessary to detect microscopic metastases, which is critical for accurate staging and treatment planning.

The initial ultrasound was done at an outside facility. Should I repeat it?

Yes, repeating the ultrasound at your institution is rated as ‘Usually Appropriate’. A dedicated, high-resolution diagnostic breast and axillary ultrasound performed by a specialized breast imager is essential to confirm the initial findings, fully characterize the lesion, evaluate the entire breast and axilla, and provide the necessary guidance for a biopsy.

Why is a core needle biopsy preferred over a fine-needle aspiration (FNA) for the primary breast mass?

A core needle biopsy provides a solid piece of tissue, which allows the pathologist to assess the tissue architecture. This is crucial for distinguishing between in-situ cancer and invasive cancer. It also provides enough tissue to perform essential biomarker testing, such as for estrogen receptor (ER), progesterone receptor (PR), and HER2 status, which directly guide treatment decisions. FNA only provides loose cells (cytology) and is insufficient for a complete diagnosis.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026